Explore
Validate
Learn
Western blot
ELISAAntibody data
- Antibody Data
- Antigen structure
- References [1]
- Comments [0]
- Validations
- Western blot [1]
- Immunohistochemistry [1]
- Other assay [4]
Submit
Validation data
Reference
Comment
Report error
- Product number
- PA5-116854 - Provider product page
- Provider
- Invitrogen Antibodies
- Product name
- MITD1 Polyclonal Antibody
- Antibody type
- Polyclonal
- Antigen
- Recombinant full-length protein
- Description
- Positive Samples: U-87MG, MCF7, Mouse thymus, Mouse spleen, Rat thymus, Rat spleen Immunogen sequence: MAKSGLRQDP QSTAAATVLK RAVELDSESR YPQALVCYQE GIDLLLQVLK GTKDNTKRCN LREKISKYMD RAENIKKYLD QEKEDGKYHK QIKIEENATG FSYESLFREY LNETVTEVWI EDPYIRHTHQ LYNFLRFCEM LIKRPCKVKT IHLLTSLDEG IEQVQQSRGL QEIEESLRSH GVLLEVQYSS SIHDREIRFN NGWMIKIGRG LDYFKKPQSR FSLGYCDFDL RPCHETTVDI FHKKHTKNI
- Reactivity
- Human, Mouse, Rat
- Host
- Rabbit
- Isotype
- IgG
- Vial size
- 100 µL
- Concentration
- 0.82 mg/mL
- Storage
- -20°C, Avoid Freeze/Thaw Cycles
Submitted references MITD1 Deficiency Suppresses Clear Cell Renal Cell Carcinoma Growth and Migration by Inducing Ferroptosis through the TAZ/SLC7A11 Pathway.
Zhang Y, Li Y, Qiu Q, Chen Z, Du Y, Liu X
Oxidative medicine and cellular longevity 2022;2022:7560569
Oxidative medicine and cellular longevity 2022;2022:7560569
No comments: Submit comment
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Western blot analysis of MITD1 in extracts of various cell lines. Samples were incubated with MITD1 Polyclonal antibody (Product # PA5-116854) using a dilution of 1:1,000, followed by HRP Goat Anti-Rabbit IgG (H+L) at a dilution of 1:10,000. Lysates/proteins: 25 µg per lane. Blocking buffer: 3% nonfat dry milk in TBST. Detection: ECL Enhanced Kit. Exposure time: 180s.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Immunohistochemistry analysis of MITD1 in paraffin-embedded human liver. Samples were incubated with MITD1 Polyclonal antibody (Product # PA5-116854) using a dilution of 1:100 (40x lens). Perform microwave antigen retrieval with 10 mM PBS buffer pH 7.2 before commencing with IHC staining protocol.
Supportive validation
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 1 MITD1 was generally highly expressed in ccRRC. (a) Analysis from the GEPIA showing the expression of MITD1 in common malignant tumors. (b) The expression of MITD1 in ccRCC tissues was higher compared to the normal tissues through TCGA dataset analysis. (c) The expression of MITD1 in paired ccRCC tissues was also higher compared to the paracancerous tissues. (d, e) Relationship between MITD1 expression and tumor stage as well as that between MITD1 expression and T stage. (f) Based on the median values of MITD1 expression, patients were divided into the low-expression or high-expression group. Kaplan-Meier's survival curve of two groups through the analysis of clinical information of ccRCC in TCGA. (g) Representative blotting of MITD1 in different cell lines, and quantification of MITD1 proteins levels relative to HK-2 cells. Values are expressed as the mean +- SEM, n = 3. * P < 0.05 and *** P < 0.001.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 2 MITD1 knockdown inhibits ccRCC cell proliferation and migration. (a, b) 786-O cells or A498 cells were transfected with negative control or different si-RNA (SiMITD1-1 or SiMITD1-2). Western blot of MITD1 to test the effect of si-RNA transfection. (c, d) Knockdown of MITD1 suppressed cell growth ability in ccRCC cells (786-O and A498). (e) Proliferation of 786-O and A498 cells was suppressed by MITD1 knockdown. (f) When 786-O and A498 cells with different treatments grew to 90%-95% density, the surface of cells was scratched with a straight gap. Scratches at 0 and 24 hours were photographed and recorded under the microscope (magnification x40; scale bars = 200 mu m). Values are expressed as the mean +- SEM, n = 3.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 4 MITD1 knockdown induces ferroptosis through downregulating SLC7A11. (a) Western blot of MITD1and ferroptosis-related proteins (GPX4, SLC7A11, COX2, and ACSL4) in ccRCC cells after silencing MITD1 (SiMITD1). (b, c) 786-O cells or A498 cells were transfected with TAZ plasmid after silencing MITD1. Western blot of MITD1 and SLC7A11. (d-f) Levels of MDA, GSH, and SOD in ccRCC cells with different treatments. Values are expressed as the mean +- SEM, n = 3. * P < 0.05, relative to the control group; # P < 0.05, relative to the SiMITD1.
- Submitted by
- Invitrogen Antibodies (provider)
- Main image
- Experimental details
- Figure 6 MITD1 knockdown induces ferroptosis through the TAZ/SLC7A11 pathway. (a, b) 786-O cells or A498 cells were transfected with negative control or si-RNA for MITD1 (SiMITD1) and then were transfected with TAZ plasmid. Western blot of MITD1, SLC7A11, and TAZ. (c) Representative images of 786-O cells with DCFH-DA staining (magnification x100; scale bars = 100 mu m) after different treatments. (d-f) Levels of MDA, GSH, and SOD in ccRCC cells with different treatments. Values are expressed as the mean +- SEM, n = 3. * P < 0.05, relative to the control group; # P < 0.05, relative to the SiMITD1.
